Stocks · News reference

Tenax Therapeutics shares are trading lower after the company announced its Phase 3 LEVEL clinical trial evaluating TNX-103 did not meet its primary or key secondary endpoints.

Aug 10, 2026, 12:36 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 25, 2026, 5:06 PMBenzinga Insights
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Picard Medical (AMEX:PMI) shares moved upwards by 82.7% to $9.38 during Tuesday's regular session. The market value of their outstanding shares is at $10.5 million. As per the news, the Q2 earnings report
Read original at benzinga
AIXC AMIX CDT CELGR JUNS
BenzingaAug 11, 2026, 4:02 PMBenzinga Newsdesk
Chardan Capital Downgrades Tenax Therapeutics to Neutral, Lowers Price Target to $5
Chardan Capital analyst Gautam Chukka downgrades Tenax Therapeutics (NASDAQ:TENX) from Buy to Neutral and lowers the price target from $27 to $5.
Read original at benzinga
TENX
BenzingaAug 11, 2026, 2:19 PMBenzinga Newsdesk
Guggenheim Maintains Buy on Tenax Therapeutics, Lowers Price Target to $4
Guggenheim analyst Seamus Fernandez maintains Tenax Therapeutics (NASDAQ:TENX) with a Buy and lowers the price target from $40 to $4.
Read original at benzinga
TENX
BenzingaAug 11, 2026, 12:38 PMBenzinga Newsdesk
Evercore ISI Group Downgrades Tenax Therapeutics to In-Line, Lowers Price Target to $5
Evercore ISI Group analyst Gavin Clark-Gartner downgrades Tenax Therapeutics (NASDAQ:TENX) from Outperform to In-Line and lowers the price target from $39 to $5.
Read original at benzinga
TENX